Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29653777 | 1.00 | GPR35 (0.61) | GPR35ALDH1A1HSD17B10TSHRTDP1 | |
| SCHEMBL1751440 | 0.87 | ALDH1A1 (0.67) | GPR35ALDH1A1HSD17B10TSHRTDP1 | |
| Trinitrotoluene SCHEMBL20676 | 0.85 | ALDH1A1 (0.61) | GPR35ALDH1A1HSD17B10TSHRTDP1 | |
| Trinitrotoluene SCHEMBL891182 | 0.85 | ALDH1A1 (0.61) | GPR35ALDH1A1HSD17B10TSHRTDP1 | |
| Trinitrotoluene SCHEMBL14966251 | 0.83 | ALDH1A1 (0.59) | GPR35ALDH1A1HSD17B10TSHRTDP1 | |
| Trinitrotoluene SCHEMBL9101074 | 0.83 | ALDH1A1 (0.59) | GPR35ALDH1A1HSD17B10TSHRTDP1 | |
| Trinitrotoluene SCHEMBL9101080 | 0.83 | ALDH1A1 (0.59) | GPR35ALDH1A1HSD17B10TSHRTDP1 | |
| Trinitrotoluene SCHEMBL14966503 | 0.83 | ALDH1A1 (0.59) | GPR35ALDH1A1HSD17B10TSHRTDP1 | |
| Trinitrotoluene SCHEMBL1272395 | 0.83 | ALDH1A1 (0.59) | GPR35ALDH1A1HSD17B10TSHRTDP1 | |
| Trinitrotoluene SCHEMBL2566651 | 0.83 | ALDH1A1 (0.59) | GPR35ALDH1A1HSD17B10TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051970-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-02-15 | — | — | US | disclosed |
| CN-117321048-A | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230092163-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-03-23 | — | — | US | disclosed |
| EP-3983383-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020252240-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-2167496-B1 | AZO DYES | HUNTSMAN ADV MAT SWITZERLAND (CH) | 2014-09-24 | — | — | EP | disclosed |
| US-8231691-B2 | Azo dyes | HUNTSMAN INTERNATIONAL LLC (US) | 2012-07-31 | — | — | US | disclosed |
| US-8226758-B2 | Disperse dyes mixtures | DYSTAR COLOURS DEUTSCHLAND GMBH (DE) | 2012-07-24 | — | — | US | disclosed |
| US-8226758-B2 | Disperse dyes mixtures | DYSTAR COLOURS DEUTSCHLAND GMBH (DE) | 2012-07-24 | — | — | US | disclosed |
| US-8003624-B2 | Functionally selective ALPHA2C adrenoreceptor agonists | SCHERING CORPORATION (US) | 2011-08-23 | — | — | US | disclosed |
| CN-101296920-A | Imidazole derivatives as functionally selective alpha 2C adrenoreceptor agonists | SCHERING CORP AND PHARMACOPEIA (US) | 2008-10-29 | — | — | CN | disclosed |
| WO-2008100457-A2 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| EP-1945626-A1 | IMIDAZOLE DERIVATIVES AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2008074719-A1 | DISPERSE DYES MIXTURES | DYSTAR TEXTILFARBEN GMBH & CO DEUTSCHLAND KG (DE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20070099872-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2007-05-03 | — | — | US | disclosed |
| WO-2007024944-A1 | IMIDAZOLE DERIVATIVES AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
| US-5969155-A | Conversion of trinitrotoluene into high value compounds | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0045423-B1 | PROCESS FOR THE ALPHA-HALOGENATION OF POSSIBLY SUBSTITUTED METHYL AROMATICS | BAYER AG (DE) | 1984-02-22 | — | — | EP | disclosed |
| EP-0045423-A1 | Process for the alpha-halogenation of possibly substituted methyl aromatics | BAYER AG (DE) | 1982-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092163-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | GPR35 592/4885ALDH1A1 4633/4885HSD17B10 4333/4885 |
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | GPR35 185/4885ALDH1A1 805/4885HSD17B10 1797/4885 |
| US-20070099872-A1 | Functionally selective alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | GPR35 185/4885ALDH1A1 805/4885HSD17B10 1797/4885 |
| US-20240051970-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | GPR35 522/4885ALDH1A1 4654/4885HSD17B10 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.